Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754001 | 0.89 | TLR7 (0.40) | TLR7TLR8NLRP3 | |
| SCHEMBL1753818 | 0.87 | TLR7 (0.49) | TLR7TLR8NLRP3 | |
| SCHEMBL1753624 | 0.86 | TLR7 (0.40) | TLR7TLR8NLRP3 | |
| SCHEMBL1753625 | 0.84 | TLR7 (0.40) | TLR7TLR8NLRP3 | |
| SCHEMBL893507 | 0.80 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL893197 | 0.79 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL30773470 | 0.79 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL1753999 | 0.77 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL1753875 | 0.75 | TLR7 (0.40) | TLR7TLR8NLRP3 | |
| SCHEMBL1753995 | 0.74 | TLR7 (0.52) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | TLR7 194/4885TLR8 494/4885NLRP3 4669/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | TLR7 27/4885TLR8 152/4885NLRP3 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.